Why Altimmune, Inc.’s (ALT) Stock Is Up 5.76%
As of Friday, August 21, Altimmune, Inc.’s ALT share price has surged by 5.76%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Commentary & Analysis
Why Altimmune, Inc.’s (ALT) Stock Is Up 6.00%
As of Wednesday, August 12, Altimmune, Inc.’s ALT share price has surged by 6.00%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Altimmune, Inc.’s (ALT) Stock Is Down 5.54%
As of Friday, July 31, Altimmune, Inc.’s ALT share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Altimmune, Inc.’s (ALT) Stock Is Up 8.06%
As of Wednesday, July 01, Altimmune, Inc.’s ALT share price has surged by 8.06%, which has investors questioning if this is right time to sell.Michael Rose
Why Altimmune, Inc.’s (ALT) Stock Is Up 8.89%
As of Monday, June 22, Altimmune, Inc.’s ALT share price has surged by 8.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ALT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $573.8 | $286.3 | 38% |
|
| Shares Out (Mil) | 185.4 | 54.2 | 75% |
|
| Institutional Ownership | 99.2% | 92.8% | 86% |
|
| Float (Mil) | 164.4 | 39.7 | 71% |
|
| Beta | 0.17 | 0.94 | 11% |
|
| Avg Daily Volume (000s) | 4,866 | 534 | 92% |
|
| Price Change (52-week) |
(18.5%) | 58.7% | 30% |
|
| Growth | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.4%) | (10.1%) | 27% |
|
| EPS (5yr) | 12.2% | 16.0% | 51 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.6%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.137) | ($0.588) | ($0.668) | |
| Month Ago EPS | ($0.167) | ($0.709) | ($0.859) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.177) | ($0.740) | ($0.902) | |
| Year/Year Chg | 11.4% | (41.2%) | (23.5%) | |
| Financials | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($92) | ($43) | 12% |
|
| EPS (TTM) | ($0.726) | ($1.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($120) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $36 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $270 | $160 | 29% |
|
| Valuation | ALT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.21 | 2.77 | 29% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (25.6%) | (47.3%) | 18% |
|
| ROE | (28.9%) | (55.0%) | 20% |
|
| Liabilities to Assets | 10.1% | 29.6% | 6% |
|
| F-Score | 3 | 2 | 18% |
|
Altimmune, Inc. did not pass any screens on 8/20/2026.
